NCT07405762 Early Neurovascular Decoupling Trajectories After Revascularization in Acute Ischemic Stroke
| NCT ID | NCT07405762 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2026-02-05 |
| Primary Completion | 2028-06-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2026-02-05 with a primary completion date of 2028-06-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Recanalization therapy is the standard treatment for acute ischemic stroke (AIS), yet patient outcomes remain highly heterogeneous. The underlying mechanisms of this variability are not fully understood. Neurovascular coupling (NVC), the tight link between neural activity and cerebral blood flow, is fundamental for brain function. Its disruption (neurovascular decoupling) after stroke is hypothesized to be a key determinant of recovery, but its dynamic early trajectory and predictive value for long-term functional recovery are poorly characterized. Purpose: This observational study aims to delineate the early trajectory of neurovascular decoupling following endovascular thrombectomy in AIS patients and to investigate its association with long-term functional outcome. We seek to construct a single composite biomarker by integrating multimodal data, and to evaluate its predictive value for 90-day recovery. Methods: A prospective cohort of AIS patients who undergo successful endovascular thrombectomy will be enrolled. Multimodal monitoring will be performed at specific early time points: within Days 1-3 and at Day 7 post-procedure. Assessments include: Transcranial Doppler (TCD) for cerebral hemodynamics, Electroencephalography (EEG) for neural activity, and F-wave studies for spinal motoneuron excitability. Clinical severity will be assessed using the National Institutes of Health Stroke Scale (NIHSS) concurrently. The primary outcome is the early trajectory of a composite neurovascular decoupling index. The key predictive relationship between this trajectory and 90-day functional status (assessed using the modified Rankin Scale, mRS) will be evaluated. Significance: This study will provide novel insights into the early neurophysiological changes following successful thrombectomy. By defining the trajectory of neurovascular decoupling in the critical first week and linking it to long-term function, the findings may contribute to the development of early predictive models and guide personalized rehabilitation strategies.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 85 years 2. Acute ischemic stroke due to occlusion of the anterior circulation large vessel (terminal internal carotid artery, or M1/M2 segment of the middle cerebral artery), confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). 3. Underwent endovascular thrombectomy with successful reperfusion, defined as a post-procedural modified Thrombolysis in Cerebral Infarction (mTICI) grade of 2b or 3. 4. Time from symptom onset to femoral artery puncture is ≤ 24 hours. 5. Written informed consent is provided by the patient or their legally authorized representative. Exclusion Criteria: 1. Pre-stroke disability defined as a modified Rankin Scale (mRS) score ≥ 2. 2. Severe impairment of consciousness within 24 hours post-thrombectomy, defined as a Glasgow Coma Scale (GCS) score ≤ 8. 3. Inadequate temporal bone window preventing acquisition of stable blood flow signals by Transcranial Doppler (TCD). 4. Conditions that may significantly compromise electroencephalography (EEG) quality, such as history of significant traumatic brain injury, skull defect, or intracranial metallic devices. 5. Conditions that may invalidate F-wave studies, including peripheral neuropathy, cervical radiculopathy, or primary disease of the target muscles. 6. Concurrent severe organ failure, malignancy, or a life expectancy of less than 3 months. 7. Pregnancy or lactation.
Contact & Investigator
Lang Jin
PRINCIPAL INVESTIGATOR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT07405762 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07405762 currently recruiting?
Yes, NCT07405762 is actively recruiting participants. Contact the research team at silencelang@163.com for enrollment information.
Where is the NCT07405762 trial being conducted?
This trial is being conducted at Xi'an, China, Xi'an, China.
Who is sponsoring the NCT07405762 clinical trial?
NCT07405762 is sponsored by Xijing Hospital. The principal investigator is Lang Jin at Xijing Hospital. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.